Meet ApplyKite Twin, the application assistant that learns with you
Meet your Twin, it learns with you
Your Twin learns with you
Launch week codes:30% off annual Pro20% off monthly Pro
Ends in00h00m00s
Ends in00h00m00s
Eiko Saito
Associate Professor
Research Interests
Explore related searches
Articles (20)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
There has been growing evidence suggesting that diabetes may be associated with increased liver cancer risk. However, studies conducted in Asian countries are limited. This project considered data of 968,738 adults pooled from 20 cohort studies of Asia Cohort Consortium to examine the association between baseline diabetes and liver cancer incidence and mortality. Cox proportional hazard model and competing risk approach was used for pooled data. Two‐stage meta‐analysis across studies was also done. There were 839,194 subjects with valid data regarding liver cancer incidence (5654 liver cancer cases [48.29/100,000 person‐years]), follow‐up time and baseline diabetes (44,781 with diabetes [5.3%]). There were 747,198 subjects with valid data regarding liver cancer mortality (5020 liver cancer deaths [44.03/100,000 person‐years]), follow‐up time and baseline diabetes (43,243 with diabetes [5.8%]). Hazard ratio (HR) (95% confidence interval [95%CI]) of liver cancer diagnosis in those with vs. without baseline diabetes was 1.97 (1.79, 2.16) ( p < .0001) after adjusting for baseline age, gender, body mass index, tobacco smoking, alcohol use, and heterogeneity across studies ( n = 586,072; events = 4620). Baseline diabetes was associated with increased cumulative incidence of death due to liver cancer (adjusted HR (95%CI) = 1.97 (1.79, 2.18); p < .0001) ( n = 595,193; events = 4110). A two‐stage meta‐analytic approach showed similar results. This paper adds important population‐based evidence to current literature regarding the increased incidence and mortality of liver cancer in adults with diabetes. The analysis of data pooled from 20 studies of different Asian countries and the meta‐analysis across studies with large number of subjects makes the results robust.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (18)
George Downward
University Medical Center Groningen
Erika Ota
St. Luke's International University
Paolo Boffetta
-
Melissa A Merritt
Senior Research Fellow
University of Sydney
Katharina da Silva Lopes
Junior Associate Professor
St. Luke's International University
Md. Shafiur Rahman
Junior Associate Professor
Kanagawa University of Human Services
Xin Yin
National University of Singapore
Sang Wook Yi
Professor
Asan Medical Center, University of Ulsan College of Medicine
Md. Obaidur Rahman
Research Scientist
St. Luke's International University
Arash Etemadi
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Sarah K. Abe
Section Head
National Cancer Center Institute for Cancer Control
Aesun Shin
-
Daichi Suzuki
Assistant Professor
Josai University
Naoko Arata
Chief of Division of Maternal Medicine
National Center For Child Health and Development
Noyuri Yamaji
Senior Lecturer
Showa University
Yuriko N Koyanagi
Aichi Cancer Center
Sayada Zartasha Kazmi
Imperial College London
Hidemi Ito
Division Chief
Aichi Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.